Timing of antitubulin therapy: does it matter?

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.

Breast cancer research and treatment·2016

Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer.

The pharmacogenomics journal·2013

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.

Annals of oncology : official journal of the European Society for Medical Oncology·2012

Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.

Annals of oncology : official journal of the European Society for Medical Oncology·2008

Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study.

Annals of oncology : official journal of the European Society for Medical Oncology·2005

The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2002

Incidence, Management, and Clinical Outcomes of Cardiovascular Adverse Events in Patients Receiving ALK Inhibitors for Advanced Non-Small Cell Lung Cancer: A Real-World Single-Center Analysis.

Cancer investigation·2026

Optimizing Cancer Drug Treatments Using Big Data Integration of Genomic and Clinical Data for Personalized Medicine.

Cancer investigation·2026

The Effect of Melatonin on Sleep Quality, Anxiety, and Depression in Patients with Primary Breast Cancer Undergoing Adjuvant Chemotherapy Type: A Randomized, Double-Blind, Placebo-Controlled Trial.

Cancer investigation·2026

A Comparative Analysis of TIRADS and ATA Classification Systems in Determining the Malignancy of Thyroid Nodules.

Cancer investigation·2026

Racial Differences in Outcomes Among Patients with Multiple Myeloma Treated at a Myeloma Center of Excellence: A Retrospective Cohort Study.

Cancer investigation·2026

Redefining Oligometastatic Pancreatic Ductal Adenocarcinoma: Biology, Diagnosis, and Precision Multimodal Therapy.

Cancer investigation·2026

Control of Intraocular Metastases of ALK-Rearranged Non-Small Cell Lung Cancer with Sequential Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: A Report of 2 Cases and Review of the Literature.

Case reports in oncology·2026

TP53 mutation drives unique transcriptional and functional vulnerabilities independent of del(17p) in multiple myeloma.

iScience·2026

Immunotherapy Efficacy in SMARC-Altered Cancers: A pan-cancer analysis of clinical outcomes in response to immune checkpoint inhibition.

iScience·2026

Hierarchical ROS-scavenging hydrogel system for coordinating the modulation of RGC necroptosis and oxidative stress in an acute glaucoma model.

Bioactive materials·2026

Does Combination Therapy With a Glucagon-Like Peptide-1 Receptor Agonist and a Sodium-Glucose Cotransporter 2 Inhibitor Enhance Cardiovascular and Renal Protection in People With Type 2 Diabetes Mellitus?

Cureus·2026

Arctigenin discovered by high-throughput screening ameliorates doxorubicin-induced cardiotoxicity as a novel natural KEAP1-NRF2 inhibitor.

Journal of pharmaceutical analysis·2026

Related Experiment Videos

Timing of antitubulin therapy: does it matter?

Related Concept Videos

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.

Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer.

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.

Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.

Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study.

The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer.

Incidence, Management, and Clinical Outcomes of Cardiovascular Adverse Events in Patients Receiving ALK Inhibitors for Advanced Non-Small Cell Lung Cancer: A Real-World Single-Center Analysis.

Optimizing Cancer Drug Treatments Using Big Data Integration of Genomic and Clinical Data for Personalized Medicine.

The Effect of Melatonin on Sleep Quality, Anxiety, and Depression in Patients with Primary Breast Cancer Undergoing Adjuvant Chemotherapy Type: A Randomized, Double-Blind, Placebo-Controlled Trial.

A Comparative Analysis of TIRADS and ATA Classification Systems in Determining the Malignancy of Thyroid Nodules.

Racial Differences in Outcomes Among Patients with Multiple Myeloma Treated at a Myeloma Center of Excellence: A Retrospective Cohort Study.

Redefining Oligometastatic Pancreatic Ductal Adenocarcinoma: Biology, Diagnosis, and Precision Multimodal Therapy.

Control of Intraocular Metastases of ALK-Rearranged Non-Small Cell Lung Cancer with Sequential Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: A Report of 2 Cases and Review of the Literature.

TP53 mutation drives unique transcriptional and functional vulnerabilities independent of del(17p) in multiple myeloma.

Immunotherapy Efficacy in SMARC-Altered Cancers: A pan-cancer analysis of clinical outcomes in response to immune checkpoint inhibition.

Hierarchical ROS-scavenging hydrogel system for coordinating the modulation of RGC necroptosis and oxidative stress in an acute glaucoma model.

Does Combination Therapy With a Glucagon-Like Peptide-1 Receptor Agonist and a Sodium-Glucose Cotransporter 2 Inhibitor Enhance Cardiovascular and Renal Protection in People With Type 2 Diabetes Mellitus?

Arctigenin discovered by high-throughput screening ameliorates doxorubicin-induced cardiotoxicity as a novel natural KEAP1-NRF2 inhibitor.

Related Experiment Videos

Timing of antitubulin therapy: does it matter?

Related Concept Videos

Related Articles